Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
| Active as of 2024-11-21 |
<Citation xmlns="http://hl7.org/fhir">
<id value="179631"/>
<meta>
<versionId value="8"/>
<lastUpdated value="2024-07-18T18:00:06.465Z"/>
<profile
value="http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: Citation 179631</b></p><a name="179631"> </a><a name="hc179631"> </a><a name="179631-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">version: 8; Last updated: 2024-07-18 18:00:06+0000</p><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-journal-article-citation.html">JournalArticleCitation</a></p></div><p><b>url</b>: <a href="Citation-179631.html">Citation 19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.</a></p><p><b>identifier</b>: FEvIR Object Identifier/179631, <code>https://pubmed.ncbi.nlm.nih.gov</code>/19029421, <a href="http://terminology.hl7.org/6.1.0/NamingSystem-uri.html" title="As defined by RFC 3986 (http://www.ietf.org/rfc/rfc3986.txt)(with many schemes defined in many RFCs). For OIDs and UUIDs, use the URN form (urn:oid:(note: lowercase) and urn:uuid:). See http://www.ietf.org/rfc/rfc3001.txt and http://www.ietf.org/rfc/rfc4122.txt
This oid is used as an identifier II.root to indicate the the extension is an absolute URI (technically, an IRI). Typically, this is used for OIDs and GUIDs. Note that when this OID is used with OIDs and GUIDs, the II.extension should start with urn:oid or urn:uuid:
Note that this OID is created to aid with interconversion between CDA and FHIR - FHIR uses urn:ietf:rfc:3986 as equivalent to this OID. URIs as identifiers appear more commonly in FHIR.
This OID may also be used in CD.codeSystem.">Uniform Resource Identifier (URI)</a>/urn:oid:2.16.840.1.113883.4.642.40.44.15.42</p><p><b>version</b>: 2.0.0-ballot</p><p><b>title</b>: 19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.</p><p><b>status</b>: Active</p><p><b>date</b>: 2024-11-21 14:09:14+0000</p><p><b>publisher</b>: HL7 International / Clinical Decision Support</p><p><b>contact</b>: HL7 International / Clinical Decision Support: <a href="http://www.hl7.org/Special/committees/dss">http://www.hl7.org/Special/committees/dss</a></p><p><b>description</b>: </p><div><p>This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.</p>
</div><h3>UseContexts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style="display: none">*</td><td><a href="http://hl7.org/fhir/R5/codesystem-citation-classification-type.html#citation-classification-type-fevir-platform-use">Citation Classification Type fevir-platform-use</a>: FEvIR Platform Use</td><td><span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier medline-base}">Medline Base</span></td></tr></table><p><b>jurisdiction</b>: <span title="Codes:{http://unstats.un.org/unsd/methods/m49/m49.htm 001}">World</span></p><p><b>copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>
</div><p><b>approvalDate</b>: 2009-01-13</p><p><b>lastReviewDate</b>: 2023-02-02</p><p><b>author</b>: Computable Publishing®: MEDLINE-to-FEvIR Converter: </p><blockquote><p><b>classification</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/citation-classification-type citation-source}">Citation Source</span></p><p><b>classifier</b>: <span title="Codes:">MEDLINE</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/citation-classification-type medline-owner}">MEDLINE Citation Owner</span></p><p><b>classifier</b>: <span title="Codes:{https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value NLM}">National Library of Medicine, Index Section</span></p></blockquote><p><b>currentState</b>: <span title="Codes:{http://hl7.org/fhir/citation-status-type medline-medline}">Medline Citation Status of Medline</span>, <span title="Codes:{http://hl7.org/fhir/citation-status-type pubmed-publication-status-ppublish}">PubMed PublicationStatus of ppublish</span></p><blockquote><p><b>statusDate</b></p><p><b>activity</b>: <span title="Codes:{http://hl7.org/fhir/citation-status-type pubmed-pubstatus-pubmed}">PubMed Pubstatus of Pubmed</span></p><p><b>period</b>: ?? --> 2008-11-26 09:00:00+0000</p></blockquote><blockquote><p><b>statusDate</b></p><p><b>activity</b>: <span title="Codes:{http://hl7.org/fhir/citation-status-type pubmed-pubstatus-medline}">PubMed Pubstatus of Medline</span></p><p><b>period</b>: ?? --> 2009-01-14 09:00:00+0000</p></blockquote><blockquote><p><b>statusDate</b></p><p><b>activity</b>: <span title="Codes:{http://hl7.org/fhir/citation-status-type pubmed-pubstatus-entrez}">PubMed Pubstatus of Entrez</span></p><p><b>period</b>: ?? --> 2008-11-26 09:00:00+0000</p></blockquote><blockquote><p><b>statusDate</b></p><p><b>activity</b>: <span title="Codes:{http://hl7.org/fhir/citation-status-type pubmed-pubstatus-pmc-release}">PubMed Pubstatus of PMC release</span></p><p><b>period</b>: ?? --> 2009-12-20</p></blockquote><blockquote><p><b>citedArtifact</b></p><p><b>identifier</b>: <code>https://pubmed.ncbi.nlm.nih.gov</code>/19029421, <code>https://www.ncbi.nlm.nih.gov/pmc/</code>/PMC3864402, <code>https://doi.org</code>/10.1200/JCO.2007.15.9830, pii/JCO.2007.15.9830</p><h3>Titles</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Language</b></td><td><b>Text</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/title-type primary}">Primary title</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">English</span></td><td><div><p>Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.</p>
</div></td></tr></table><h3>Abstracts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Text</b></td></tr><tr><td style="display: none">*</td><td><div><p><strong>PURPOSE:</strong> We conducted a phase III trial in patients with previously untreated metastatic prostate cancer to test the hypothesis that three 8-week cycles of ketoconazole and doxorubicin alternating with vinblastine and estramustine, given in addition to standard androgen deprivation, would delay the appearance of castrate-resistant disease.
<strong>PATIENTS AND METHODS:</strong> Eligible patients had metastatic prostate cancer threatening enough to justify sustained androgen ablation and were fit enough for chemotherapy. The primary end point was time to castrate-resistant progression as shown by increasing prostate-specific antigen, new radiographic lesions, worsening cancer-related symptoms, or receipt of any other systemic therapy.
<strong>RESULTS:</strong> Three hundred six patients were registered; 286 are reported. Median time to progression was 24 months (95% CI, 18 to 39 months) in the standard therapy arm, and 35 months (95% CI, 26 to 44 months) in the chemohormonal group (P = .39). At median follow-up of 6.4 years, overall survival was 5.4 years (95% CI, 4.7 to 7.8 years) in the standard therapy arm versus 6.1 years (95% CI, 5.1 to 10.1 years; P = .41). Prostate-specific antigen kinetics at the time of androgen ablation and the nadir after hormone treatment were strongly correlated with survival. Chemotherapy significantly increased the burden of therapy, with 51% of patients experiencing an adverse event of grade 3 or worse, especially thromboembolic events.
<strong>CONCLUSION:</strong> There is no role for ketoconazole and doxorubicin alternating with vinblastine and estramustine before emergence of a castrate-resistant phenotype.</p>
</div></td></tr></table><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Jemal A, Siegel R, Ward E, et al: Cancer Statistics, 2007. CA Cancer J Clin 57:43-66, 2007</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/17237035/">https://pubmed.ncbi.nlm.nih.gov/17237035/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/17237035</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Yagoda A, Petrylak D: Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71:1098-1109, 1993</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/7679039/">https://pubmed.ncbi.nlm.nih.gov/7679039/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/7679039</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Beer T, Raghavan D: Chemotherapy for hormone-refractory prostate cancer: Beauty is in the eye of the beholder. Prostate 45:184-193, 2000</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/11027418/">https://pubmed.ncbi.nlm.nih.gov/11027418/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/11027418</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Ellerhorst JA, Tu SM, Amato RJ, et al: Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res 3:2371-2376, 1997</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/9815636/">https://pubmed.ncbi.nlm.nih.gov/9815636/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/9815636</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Smith DC, Esper P, Strawderman M, et al: Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 17:1664-1671, 1999</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/10561202/">https://pubmed.ncbi.nlm.nih.gov/10561202/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/10561202</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Kelly WK, Curley T, Slovin S, et al: Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 19:44-53, 2001</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/11134194/">https://pubmed.ncbi.nlm.nih.gov/11134194/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/11134194</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Millikan RE, Thall PF, Lee SJ, et al: Randomized multicenter phase II trial of two multicomponent regimens in androgen independent prostate cancer. J Clin Oncol 21:878-883, 2003</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/12610188/">https://pubmed.ncbi.nlm.nih.gov/12610188/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/12610188</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520, 2004</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/15470214/">https://pubmed.ncbi.nlm.nih.gov/15470214/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/15470214</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/15470213/">https://pubmed.ncbi.nlm.nih.gov/15470213/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/15470213</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Murphy GP, Beckley S, Brady MF, et al: Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 51:1264-1272, 1983</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/6337697/">https://pubmed.ncbi.nlm.nih.gov/6337697/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/6337697</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Murphy GP, Huben RP, Priore R: Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer. Urology 28:36-40, 1986</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/3523938/">https://pubmed.ncbi.nlm.nih.gov/3523938/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/3523938</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Osborne CK, Blumenstein B, Crawford ED, et al: Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: Final results of a randomized Southwest Oncology Group study. J Clin Oncol 8:1675-1682, 1990</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/2213104/">https://pubmed.ncbi.nlm.nih.gov/2213104/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/2213104</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Pummer K, Lehnert M, Stettner H, et al: Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol 32:81-85, 1997. (suppl)</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/9267791/">https://pubmed.ncbi.nlm.nih.gov/9267791/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/9267791</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Janknegt RA, Boon TA, van de Beek C, et al: Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: A randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. Urology 49:411-420, 1997</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/9123707/">https://pubmed.ncbi.nlm.nih.gov/9123707/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/9123707</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Fontana D, Bertetto O, Fasolis G, et al: Randomized comparison of goserelin acetate versus mitomycin C plus goserelin acetate in previously untreated prostate cancer patients with bone metastases. Tumori 84:39-44, 1998</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/9619712/">https://pubmed.ncbi.nlm.nih.gov/9619712/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/9619712</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Boel K, Van Poppel H, Goethuys H, et al: Mitomycin C for metastatic prostate cancer: Final analysis of a randomized trial. Anticancer Res 19:2157-2161, 1999</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/10472324/">https://pubmed.ncbi.nlm.nih.gov/10472324/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/10472324</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>de Reijke TM, Keuppens FI, Whelan P, et al: Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: The final results of a European organization for research in cancer therapy genitourinary group trial. J Urol 162:1658-1664, 1999</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/10524892/">https://pubmed.ncbi.nlm.nih.gov/10524892/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/10524892</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Kuriyama M, Takanhashi Y, Sahashi M, et al: Prospective and randomized comparison of combined androgen blockade versus combination with oral UFT as an initial treatment for prostate cancer. Jpn J Clin Oncol 31:18-24, 2001</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/11256836/">https://pubmed.ncbi.nlm.nih.gov/11256836/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/11256836</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Noguchi M, Noda Shinshi, Yoshida M, et al: Chemohormonal therapy as primary treatment for metastatic prostate cancer: A randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. Int J Urol 11:103-109, 2004</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/14706014/">https://pubmed.ncbi.nlm.nih.gov/14706014/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/14706014</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>citation</b>: </p><div><p>Fisher LD, Belle GV: Biostatistics: A Methodology For the Health Sciences. New York, NY, John Wiley, 1993</p>
</div></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>citation</b>: </p><div><p>Randles RH, Wolfe DA: Introduction to the Theory of Nonparametric Statistics. New York, NY, John Wiley, 1979</p>
</div></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>citation</b>: </p><div><p>Lawless JF: Statistical Models and Methods for Lifetime Data. New York, NY, John Wiley, 1982</p>
</div></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Hussain M, Tangen CM, Higano C, et al: Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from the Southwest Oncology Group trial 9346 (INT-0162). J Clin Oncol 24:3984-3990, 2006</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/16921051/">https://pubmed.ncbi.nlm.nih.gov/16921051/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/16921051</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Stewart AJ, Scher HI, Chen M-H, et al: Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol 23:6556-6560, 2005</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/16170163/">https://pubmed.ncbi.nlm.nih.gov/16170163/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/16170163</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Pettaway CA, Pisters LL, Troncoso P, et al: Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: Feasibility and preliminary results. J Clin Oncol 18:1050-1057, 2000</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/10694556/">https://pubmed.ncbi.nlm.nih.gov/10694556/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/10694556</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Friedman J, Dunn RL, Wood D, et al: Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer. J Urol 179:911-916, 2008</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/18207190/">https://pubmed.ncbi.nlm.nih.gov/18207190/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/18207190</p></blockquote><blockquote><p><b>publicationForm</b></p><blockquote><p><b>publishedIn</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/published-in-type D020492}">Periodical</span></p><p><b>identifier</b>: Electronic ISSN Type/1527-7755, ISOAbbreviation/J Clin Oncol, ISSN Linking/0732-183X, Medline Title Abbreviation/J Clin Oncol, NLM Unique ID/8309333</p><p><b>title</b>: Journal of clinical oncology : official journal of the American Society of Clinical Oncology</p><p><b>publisherLocation</b>: United States</p></blockquote><p><b>citedMedium</b>: <span title="Codes:{http://hl7.org/fhir/cited-medium internet}">Internet</span></p><p><b>volume</b>: 26</p><p><b>issue</b>: 36</p><p><b>articleDate</b>: 2008-12-20</p><p><b>publicationDateText</b>: 2008-Dec-20</p><p><b>language</b>: <span title="Codes:{urn:ietf:bcp:47 en}">English</span></p><p><b>pageString</b>: 5936-42</p></blockquote><blockquote><p><b>publicationForm</b></p><p><b>citedMedium</b>: <span title="Codes:{http://hl7.org/fhir/cited-medium internet-without-issue}">Internet without issue</span></p><p><b>articleDate</b>: 2008-11-24</p></blockquote><blockquote><p><b>webLocation</b></p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/artifact-url-classifier abstract}">Abstract</span></p><p><b>url</b>: <a href="https://pubmed.ncbi.nlm.nih.gov/19029421/">https://pubmed.ncbi.nlm.nih.gov/19029421/</a></p></blockquote><blockquote><p><b>webLocation</b></p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/artifact-url-classifier doi-based}">DOI Based</span></p><p><b>url</b>: <a href="https://doi.org/10.1200/JCO.2007.15.9830">https://doi.org/10.1200/JCO.2007.15.9830</a></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type publishing-model}">Publishing Model</span></p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier Print-Electronic}">Print Electronic</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type chemical}">Chemical</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ D000726}">Androgen Antagonists</span>, <span title="Codes:{https://meshb.nlm.nih.gov/ D000903}">Antibiotics, Antineoplastic</span>, <span title="Codes:{https://meshb.nlm.nih.gov/ D018906}">Antineoplastic Agents, Alkylating</span>, <span title="Codes:{https://meshb.nlm.nih.gov/ D000972}">Antineoplastic Agents, Phytogenic</span>, <span title="Codes:{https://www.cas.org/support/documentation/chemical-substances 35LT29625A}, {https://meshb.nlm.nih.gov/ D004961}">Estramustine</span>, <span title="Codes:{https://www.cas.org/support/documentation/chemical-substances 5V9KLZ54CY}, {https://meshb.nlm.nih.gov/ D014747}">Vinblastine</span>, <span title="Codes:{https://www.cas.org/support/documentation/chemical-substances 80168379AG}, {https://meshb.nlm.nih.gov/ D004317}">Doxorubicin</span>, <span title="Codes:{https://www.cas.org/support/documentation/chemical-substances R9400W927I}, {https://meshb.nlm.nih.gov/ D007654}">Ketoconazole</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}">MeSH heading</span></p><p><b>artifactAssessment</b>: <a href="#hc179631/meshHeading0">ArtifactAssessment: artifact[x] = this resource</a></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type publication-type}">Publication type</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ D017428}">Clinical Trial, Phase III</span>, <span title="Codes:{https://meshb.nlm.nih.gov/ D016428}">Journal Article</span>, <span title="Codes:{https://meshb.nlm.nih.gov/ D016449}">Randomized Controlled Trial</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type knowledge-artifact-type}">Knowledge Artifact Type</span></p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>artifactAssessment</b>: Classifier added by Computable Publishing LLC</p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type citation-subset}">Citation subset</span></p><p><b>classifier</b>: <span title="Codes:{https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset IM}">IM</span></p></blockquote><blockquote><p><b>contributorship</b></p><p><b>complete</b>: true</p><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc179631/contributor0">Millikan RE</a></p><p><b>forenameInitials</b>: RE</p><p><b>affiliation</b>: Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, 1155 Pressler, CPB7.3462, Houston, TX 77030, USA. rmillika@mdanderson.org</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc179631/contributor1">Wen S</a></p><p><b>forenameInitials</b>: S</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc179631/contributor2">Pagliaro LC</a></p><p><b>forenameInitials</b>: LC</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc179631/contributor3">Brown MA</a></p><p><b>forenameInitials</b>: MA</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc179631/contributor4">Moomey B</a></p><p><b>forenameInitials</b>: B</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc179631/contributor5">Do KA</a></p><p><b>forenameInitials</b>: KA</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc179631/contributor6">Logothetis CJ</a></p><p><b>forenameInitials</b>: CJ</p></blockquote></blockquote></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor0</b></p><a name="179631/contributor0"> </a><a name="hc179631/contributor0"> </a><a name="179631/contributor0-en-US"> </a><p><b>name</b>: Randall E Millikan </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor1</b></p><a name="179631/contributor1"> </a><a name="hc179631/contributor1"> </a><a name="179631/contributor1-en-US"> </a><p><b>name</b>: Sijin Wen </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor2</b></p><a name="179631/contributor2"> </a><a name="hc179631/contributor2"> </a><a name="179631/contributor2-en-US"> </a><p><b>name</b>: Lance C Pagliaro </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor3</b></p><a name="179631/contributor3"> </a><a name="hc179631/contributor3"> </a><a name="179631/contributor3-en-US"> </a><p><b>name</b>: Melissa A Brown </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor4</b></p><a name="179631/contributor4"> </a><a name="hc179631/contributor4"> </a><a name="179631/contributor4-en-US"> </a><p><b>name</b>: Brenda Moomey </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor5</b></p><a name="179631/contributor5"> </a><a name="hc179631/contributor5"> </a><a name="179631/contributor5-en-US"> </a><p><b>name</b>: Kim-Anh Do </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor6</b></p><a name="179631/contributor6"> </a><a name="hc179631/contributor6"> </a><a name="179631/contributor6-en-US"> </a><p><b>name</b>: Christopher J Logothetis </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: ArtifactAssessment #meshHeading0</b></p><a name="179631/meshHeading0"> </a><a name="hc179631/meshHeading0"> </a><a name="179631/meshHeading0-en-US"> </a><p><b>artifact</b>: <a href="#hc179631">Citation 19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.</a></p><blockquote><p><b>content</b></p><p><b>informationType</b>: Classifier</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ D000328}">Adult</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">qualifier</span></td><td><span title="Codes:">is not a major topic</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: Classifier</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ D000368}">Aged</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">qualifier</span></td><td><span title="Codes:">is not a major topic</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: Classifier</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ D000369}">Aged, 80 and over</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">qualifier</span></td><td><span title="Codes:">is not a major topic</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: Classifier</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ D000726}">Androgen Antagonists</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title="Codes:">qualifier</span></p><p><b>classifier</b>: <span title="Codes:">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title="Codes:">qualifier</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ Q000627}">therapeutic use</span></p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">is Major topic</span></td><td><span title="Codes:{https://ncithesaurus.nci.nih.gov/ncitbrowser C49488}">Yes</span></td></tr></table></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: Classifier</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ D000903}">Antibiotics, Antineoplastic</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title="Codes:">qualifier</span></p><p><b>classifier</b>: <span title="Codes:">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title="Codes:">qualifier</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ Q000008}">administration & dosage</span></p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">is Major topic</span></td><td><span title="Codes:{https://ncithesaurus.nci.nih.gov/ncitbrowser C49487}">No</span></td></tr></table></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: Classifier</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ D018906}">Antineoplastic Agents, Alkylating</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title="Codes:">qualifier</span></p><p><b>classifier</b>: <span title="Codes:">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title="Codes:">qualifier</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ Q000008}">administration & dosage</span></p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">is Major topic</span></td><td><span title="Codes:{https://ncithesaurus.nci.nih.gov/ncitbrowser C49487}">No</span></td></tr></table></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: Classifier</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ D000972}">Antineoplastic Agents, Phytogenic</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title="Codes:">qualifier</span></p><p><b>classifier</b>: <span title="Codes:">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title="Codes:">qualifier</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ Q000008}">administration & dosage</span></p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">is Major topic</span></td><td><span title="Codes:{https://ncithesaurus.nci.nih.gov/ncitbrowser C49487}">No</span></td></tr></table></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: Classifier</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ D000971}">Antineoplastic Combined Chemotherapy Protocols</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title="Codes:">qualifier</span></p><p><b>classifier</b>: <span title="Codes:">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title="Codes:">qualifier</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ Q000627}">therapeutic use</span></p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">is Major topic</span></td><td><span title="Codes:{https://ncithesaurus.nci.nih.gov/ncitbrowser C49488}">Yes</span></td></tr></table></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: Classifier</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ D004317}">Doxorubicin</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title="Codes:">qualifier</span></p><p><b>classifier</b>: <span title="Codes:">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title="Codes:">qualifier</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ Q000008}">administration & dosage</span></p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">is Major topic</span></td><td><span title="Codes:{https://ncithesaurus.nci.nih.gov/ncitbrowser C49487}">No</span></td></tr></table></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: Classifier</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ D004961}">Estramustine</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title="Codes:">qualifier</span></p><p><b>classifier</b>: <span title="Codes:">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title="Codes:">qualifier</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ Q000008}">administration & dosage</span></p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">is Major topic</span></td><td><span title="Codes:{https://ncithesaurus.nci.nih.gov/ncitbrowser C49487}">No</span></td></tr></table></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: Classifier</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ D006801}">Humans</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">qualifier</span></td><td><span title="Codes:">is not a major topic</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: Classifier</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ D007654}">Ketoconazole</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title="Codes:">qualifier</span></p><p><b>classifier</b>: <span title="Codes:">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title="Codes:">qualifier</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ Q000008}">administration & dosage</span></p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">is Major topic</span></td><td><span title="Codes:{https://ncithesaurus.nci.nih.gov/ncitbrowser C49487}">No</span></td></tr></table></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: Classifier</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ D008297}">Male</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">qualifier</span></td><td><span title="Codes:">is not a major topic</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: Classifier</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ D008875}">Middle Aged</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">qualifier</span></td><td><span title="Codes:">is not a major topic</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: Classifier</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ D009362}">Neoplasm Metastasis</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">qualifier</span></td><td><span title="Codes:">is not a major topic</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: Classifier</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ D011471}">Prostatic Neoplasms</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title="Codes:">qualifier</span></p><p><b>classifier</b>: <span title="Codes:">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title="Codes:">qualifier</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ Q000188}">drug therapy</span></p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">is Major topic</span></td><td><span title="Codes:{https://ncithesaurus.nci.nih.gov/ncitbrowser C49488}">Yes</span></td></tr></table></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title="Codes:">qualifier</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ Q000401}">mortality</span></p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">is Major topic</span></td><td><span title="Codes:{https://ncithesaurus.nci.nih.gov/ncitbrowser C49487}">No</span></td></tr></table></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: Classifier</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ D014747}">Vinblastine</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title="Codes:">qualifier</span></p><p><b>classifier</b>: <span title="Codes:">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title="Codes:">qualifier</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ Q000008}">administration & dosage</span></p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">is Major topic</span></td><td><span title="Codes:{https://ncithesaurus.nci.nih.gov/ncitbrowser C49487}">No</span></td></tr></table></blockquote></blockquote></blockquote></div>
</text>
<contained>
<Practitioner>
<id value="contributor0"/>
<name>
<family value="Millikan"/>
<given value="Randall E"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor1"/>
<name>
<family value="Wen"/>
<given value="Sijin"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor2"/>
<name>
<family value="Pagliaro"/>
<given value="Lance C"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor3"/>
<name>
<family value="Brown"/>
<given value="Melissa A"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor4"/>
<name>
<family value="Moomey"/>
<given value="Brenda"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor5"/>
<name>
<family value="Do"/>
<given value="Kim-Anh"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor6"/>
<name>
<family value="Logothetis"/>
<given value="Christopher J"/>
</name>
</Practitioner>
</contained>
<contained>
<ArtifactAssessment>
<id value="meshHeading0"/>
<artifactReference>
<reference value="#"/>
<type value="Citation"/>
</artifactReference>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D000328"/>
<display value="Adult"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D000368"/>
<display value="Aged"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D000369"/>
<display value="Aged, 80 and over"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D000726"/>
<display value="Androgen Antagonists"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="Q000627"/>
<display value="therapeutic use"/>
</coding>
</classifier>
<component>
<type>
<text value="is Major topic"/>
</type>
<classifier>
<coding>
<system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
<code value="C49488"/>
<display value="Yes"/>
</coding>
</classifier>
</component>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D000903"/>
<display value="Antibiotics, Antineoplastic"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="Q000008"/>
<display value="administration & dosage"/>
</coding>
</classifier>
<component>
<type>
<text value="is Major topic"/>
</type>
<classifier>
<coding>
<system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
<code value="C49487"/>
<display value="No"/>
</coding>
</classifier>
</component>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D018906"/>
<display value="Antineoplastic Agents, Alkylating"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="Q000008"/>
<display value="administration & dosage"/>
</coding>
</classifier>
<component>
<type>
<text value="is Major topic"/>
</type>
<classifier>
<coding>
<system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
<code value="C49487"/>
<display value="No"/>
</coding>
</classifier>
</component>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D000972"/>
<display value="Antineoplastic Agents, Phytogenic"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="Q000008"/>
<display value="administration & dosage"/>
</coding>
</classifier>
<component>
<type>
<text value="is Major topic"/>
</type>
<classifier>
<coding>
<system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
<code value="C49487"/>
<display value="No"/>
</coding>
</classifier>
</component>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D000971"/>
<display value="Antineoplastic Combined Chemotherapy Protocols"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="Q000627"/>
<display value="therapeutic use"/>
</coding>
</classifier>
<component>
<type>
<text value="is Major topic"/>
</type>
<classifier>
<coding>
<system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
<code value="C49488"/>
<display value="Yes"/>
</coding>
</classifier>
</component>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D004317"/>
<display value="Doxorubicin"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="Q000008"/>
<display value="administration & dosage"/>
</coding>
</classifier>
<component>
<type>
<text value="is Major topic"/>
</type>
<classifier>
<coding>
<system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
<code value="C49487"/>
<display value="No"/>
</coding>
</classifier>
</component>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D004961"/>
<display value="Estramustine"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="Q000008"/>
<display value="administration & dosage"/>
</coding>
</classifier>
<component>
<type>
<text value="is Major topic"/>
</type>
<classifier>
<coding>
<system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
<code value="C49487"/>
<display value="No"/>
</coding>
</classifier>
</component>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D006801"/>
<display value="Humans"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D007654"/>
<display value="Ketoconazole"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="Q000008"/>
<display value="administration & dosage"/>
</coding>
</classifier>
<component>
<type>
<text value="is Major topic"/>
</type>
<classifier>
<coding>
<system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
<code value="C49487"/>
<display value="No"/>
</coding>
</classifier>
</component>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D008297"/>
<display value="Male"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D008875"/>
<display value="Middle Aged"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D009362"/>
<display value="Neoplasm Metastasis"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D011471"/>
<display value="Prostatic Neoplasms"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="Q000188"/>
<display value="drug therapy"/>
</coding>
</classifier>
<component>
<type>
<text value="is Major topic"/>
</type>
<classifier>
<coding>
<system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
<code value="C49488"/>
<display value="Yes"/>
</coding>
</classifier>
</component>
</component>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="Q000401"/>
<display value="mortality"/>
</coding>
</classifier>
<component>
<type>
<text value="is Major topic"/>
</type>
<classifier>
<coding>
<system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
<code value="C49487"/>
<display value="No"/>
</coding>
</classifier>
</component>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D014747"/>
<display value="Vinblastine"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="Q000008"/>
<display value="administration & dosage"/>
</coding>
</classifier>
<component>
<type>
<text value="is Major topic"/>
</type>
<classifier>
<coding>
<system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
<code value="C49487"/>
<display value="No"/>
</coding>
</classifier>
</component>
</component>
</content>
</ArtifactAssessment>
</contained>
<url value="https://fevir.net/resources/Citation/179631"/>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="ACSN"/>
<display value="Accession ID"/>
</coding>
<text value="FEvIR Object Identifier"/>
</type>
<system value="https://fevir.net"/>
<value value="179631"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="19029421"/>
</identifier>
<identifier>
<system value="urn:ietf:rfc:3986"/>
<value value="urn:oid:2.16.840.1.113883.4.642.40.44.15.42"/>
</identifier>
<version value="2.0.0-ballot"/>
<title
value="19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer."/>
<status value="active"/>
<date value="2024-11-21T14:09:14+00:00"/>
<publisher value="HL7 International / Clinical Decision Support"/>
<contact>
<name value="HL7 International / Clinical Decision Support"/>
<telecom>
<system value="url"/>
<value value="http://www.hl7.org/Special/committees/dss"/>
</telecom>
</contact>
<description
value="This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide."/>
<useContext>
<code>
<system value="http://hl7.org/fhir/citation-classification-type"/>
<code value="fevir-platform-use"/>
<display value="FEvIR Platform Use"/>
</code>
<valueCodeableConcept>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="medline-base"/>
<display value="Medline Base"/>
<userSelected value="false"/>
</coding>
</valueCodeableConcept>
</useContext>
<jurisdiction>
<coding>
<system value="http://unstats.un.org/unsd/methods/m49/m49.htm"/>
<code value="001"/>
<display value="World"/>
</coding>
</jurisdiction>
<copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
<approvalDate value="2009-01-13"/>
<lastReviewDate value="2023-02-02"/>
<author>
<name value="Computable Publishing®: MEDLINE-to-FEvIR Converter"/>
</author>
<classification>
<type>
<coding>
<system value="http://hl7.org/fhir/citation-classification-type"/>
<code value="citation-source"/>
<display value="Citation Source"/>
</coding>
</type>
<classifier>
<text value="MEDLINE"/>
</classifier>
</classification>
<classification>
<type>
<coding>
<system value="http://hl7.org/fhir/citation-classification-type"/>
<code value="medline-owner"/>
<display value="MEDLINE Citation Owner"/>
</coding>
</type>
<classifier>
<coding>
<system
value="https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value"/>
<code value="NLM"/>
<display value="National Library of Medicine, Index Section"/>
<userSelected value="false"/>
</coding>
</classifier>
</classification>
<currentState>
<coding>
<system value="http://hl7.org/fhir/citation-status-type"/>
<code value="medline-medline"/>
<display value="Medline Citation Status of Medline"/>
</coding>
</currentState>
<currentState>
<coding>
<system value="http://hl7.org/fhir/citation-status-type"/>
<code value="pubmed-publication-status-ppublish"/>
<display value="PubMed PublicationStatus of ppublish"/>
</coding>
</currentState>
<statusDate>
<activity>
<coding>
<system value="http://hl7.org/fhir/citation-status-type"/>
<code value="pubmed-pubstatus-pubmed"/>
<display value="PubMed Pubstatus of Pubmed"/>
</coding>
</activity>
<period>
<end value="2008-11-26T09:00:00.000Z"/>
</period>
</statusDate>
<statusDate>
<activity>
<coding>
<system value="http://hl7.org/fhir/citation-status-type"/>
<code value="pubmed-pubstatus-medline"/>
<display value="PubMed Pubstatus of Medline"/>
</coding>
</activity>
<period>
<end value="2009-01-14T09:00:00.000Z"/>
</period>
</statusDate>
<statusDate>
<activity>
<coding>
<system value="http://hl7.org/fhir/citation-status-type"/>
<code value="pubmed-pubstatus-entrez"/>
<display value="PubMed Pubstatus of Entrez"/>
</coding>
</activity>
<period>
<end value="2008-11-26T09:00:00.000Z"/>
</period>
</statusDate>
<statusDate>
<activity>
<coding>
<system value="http://hl7.org/fhir/citation-status-type"/>
<code value="pubmed-pubstatus-pmc-release"/>
<display value="PubMed Pubstatus of PMC release"/>
</coding>
</activity>
<period>
<end value="2009-12-20"/>
</period>
</statusDate>
<citedArtifact>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="19029421"/>
</identifier>
<identifier>
<system value="https://www.ncbi.nlm.nih.gov/pmc/"/>
<value value="PMC3864402"/>
</identifier>
<identifier>
<system value="https://doi.org"/>
<value value="10.1200/JCO.2007.15.9830"/>
</identifier>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="ACSN"/>
<display value="Accession ID"/>
</coding>
<text value="pii"/>
</type>
<value value="JCO.2007.15.9830"/>
</identifier>
<title>
<type>
<coding>
<system value="http://hl7.org/fhir/title-type"/>
<code value="primary"/>
<display value="Primary title"/>
</coding>
</type>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="English"/>
</coding>
</language>
<text
value="Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer."/>
</title>
<abstract>
<text
value="**PURPOSE:** We conducted a phase III trial in patients with previously untreated metastatic prostate cancer to test the hypothesis that three 8-week cycles of ketoconazole and doxorubicin alternating with vinblastine and estramustine, given in addition to standard androgen deprivation, would delay the appearance of castrate-resistant disease.
**PATIENTS AND METHODS:** Eligible patients had metastatic prostate cancer threatening enough to justify sustained androgen ablation and were fit enough for chemotherapy. The primary end point was time to castrate-resistant progression as shown by increasing prostate-specific antigen, new radiographic lesions, worsening cancer-related symptoms, or receipt of any other systemic therapy.
**RESULTS:** Three hundred six patients were registered; 286 are reported. Median time to progression was 24 months (95% CI, 18 to 39 months) in the standard therapy arm, and 35 months (95% CI, 26 to 44 months) in the chemohormonal group (P = .39). At median follow-up of 6.4 years, overall survival was 5.4 years (95% CI, 4.7 to 7.8 years) in the standard therapy arm versus 6.1 years (95% CI, 5.1 to 10.1 years; P = .41). Prostate-specific antigen kinetics at the time of androgen ablation and the nadir after hormone treatment were strongly correlated with survival. Chemotherapy significantly increased the burden of therapy, with 51% of patients experiencing an adverse event of grade 3 or worse, especially thromboembolic events.
**CONCLUSION:** There is no role for ketoconazole and doxorubicin alternating with vinblastine and estramustine before emergence of a castrate-resistant phenotype."/>
</abstract>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Jemal A, Siegel R, Ward E, et al: Cancer Statistics, 2007. CA Cancer J Clin 57:43-66, 2007"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/17237035/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="17237035"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Yagoda A, Petrylak D: Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71:1098-1109, 1993"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/7679039/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="7679039"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Beer T, Raghavan D: Chemotherapy for hormone-refractory prostate cancer: Beauty is in the eye of the beholder. Prostate 45:184-193, 2000"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/11027418/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="11027418"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Ellerhorst JA, Tu SM, Amato RJ, et al: Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res 3:2371-2376, 1997"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/9815636/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="9815636"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Smith DC, Esper P, Strawderman M, et al: Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 17:1664-1671, 1999"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/10561202/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="10561202"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Kelly WK, Curley T, Slovin S, et al: Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 19:44-53, 2001"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/11134194/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="11134194"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Millikan RE, Thall PF, Lee SJ, et al: Randomized multicenter phase II trial of two multicomponent regimens in androgen independent prostate cancer. J Clin Oncol 21:878-883, 2003"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/12610188/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="12610188"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520, 2004"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/15470214/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="15470214"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/15470213/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="15470213"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Murphy GP, Beckley S, Brady MF, et al: Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 51:1264-1272, 1983"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/6337697/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="6337697"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Murphy GP, Huben RP, Priore R: Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer. Urology 28:36-40, 1986"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/3523938/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="3523938"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Osborne CK, Blumenstein B, Crawford ED, et al: Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: Final results of a randomized Southwest Oncology Group study. J Clin Oncol 8:1675-1682, 1990"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/2213104/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="2213104"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Pummer K, Lehnert M, Stettner H, et al: Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol 32:81-85, 1997. (suppl)"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/9267791/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="9267791"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Janknegt RA, Boon TA, van de Beek C, et al: Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: A randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. Urology 49:411-420, 1997"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/9123707/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="9123707"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Fontana D, Bertetto O, Fasolis G, et al: Randomized comparison of goserelin acetate versus mitomycin C plus goserelin acetate in previously untreated prostate cancer patients with bone metastases. Tumori 84:39-44, 1998"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/9619712/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="9619712"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Boel K, Van Poppel H, Goethuys H, et al: Mitomycin C for metastatic prostate cancer: Final analysis of a randomized trial. Anticancer Res 19:2157-2161, 1999"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/10472324/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="10472324"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="de Reijke TM, Keuppens FI, Whelan P, et al: Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: The final results of a European organization for research in cancer therapy genitourinary group trial. J Urol 162:1658-1664, 1999"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/10524892/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="10524892"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Kuriyama M, Takanhashi Y, Sahashi M, et al: Prospective and randomized comparison of combined androgen blockade versus combination with oral UFT as an initial treatment for prostate cancer. Jpn J Clin Oncol 31:18-24, 2001"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/11256836/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="11256836"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Noguchi M, Noda Shinshi, Yoshida M, et al: Chemohormonal therapy as primary treatment for metastatic prostate cancer: A randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. Int J Urol 11:103-109, 2004"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/14706014/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="14706014"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<citation
value="Fisher LD, Belle GV: Biostatistics: A Methodology For the Health Sciences. New York, NY, John Wiley, 1993"/>
</relatesTo>
<relatesTo>
<type value="cites"/>
<citation
value="Randles RH, Wolfe DA: Introduction to the Theory of Nonparametric Statistics. New York, NY, John Wiley, 1979"/>
</relatesTo>
<relatesTo>
<type value="cites"/>
<citation
value="Lawless JF: Statistical Models and Methods for Lifetime Data. New York, NY, John Wiley, 1982"/>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Hussain M, Tangen CM, Higano C, et al: Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from the Southwest Oncology Group trial 9346 (INT-0162). J Clin Oncol 24:3984-3990, 2006"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/16921051/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="16921051"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Stewart AJ, Scher HI, Chen M-H, et al: Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol 23:6556-6560, 2005"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/16170163/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="16170163"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Pettaway CA, Pisters LL, Troncoso P, et al: Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: Feasibility and preliminary results. J Clin Oncol 18:1050-1057, 2000"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/10694556/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="10694556"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Friedman J, Dunn RL, Wood D, et al: Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer. J Urol 179:911-916, 2008"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/18207190/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="18207190"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<publicationForm>
<publishedIn>
<type>
<coding>
<system value="http://hl7.org/fhir/published-in-type"/>
<code value="D020492"/>
<display value="Periodical"/>
</coding>
</type>
<identifier>
<type>
<coding>
<system
value="https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#issn"/>
<code value="Electronic"/>
<display value="Electronic"/>
</coding>
<text value="Electronic ISSN Type"/>
</type>
<system value="https://portal.issn.org"/>
<value value="1527-7755"/>
</identifier>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="XX"/>
<display value="Organization identifier"/>
</coding>
<text value="ISOAbbreviation"/>
</type>
<system
value="https://www.issn.org/services/online-services/access-to-the-ltwa/"/>
<value value="J Clin Oncol"/>
</identifier>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="XX"/>
<display value="Organization identifier"/>
</coding>
<text value="ISSN Linking"/>
</type>
<system
value="https://www.issn.org/understanding-the-issn/assignment-rules/the-issn-l-for-publications-on-multiple-media/"/>
<value value="0732-183X"/>
</identifier>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="XX"/>
<display value="Organization identifier"/>
</coding>
<text value="Medline Title Abbreviation"/>
</type>
<system
value="https://www.nlm.nih.gov/tsd/cataloging/contructitleabbre.html"/>
<value value="J Clin Oncol"/>
</identifier>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="XX"/>
<display value="Organization identifier"/>
</coding>
<text value="NLM Unique ID"/>
</type>
<system
value="https://locatorplus.gov/cgi-bin/Pwebrecon.cgi?DB=local"/>
<value value="8309333"/>
</identifier>
<title
value="Journal of clinical oncology : official journal of the American Society of Clinical Oncology"/>
<publisherLocation value="United States"/>
</publishedIn>
<citedMedium>
<coding>
<system value="http://hl7.org/fhir/cited-medium"/>
<code value="internet"/>
<display value="Internet"/>
</coding>
</citedMedium>
<volume value="26"/>
<issue value="36"/>
<articleDate value="2008-12-20"/>
<publicationDateText value="2008-Dec-20"/>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="English"/>
</coding>
</language>
<pageString value="5936-42"/>
</publicationForm>
<publicationForm>
<citedMedium>
<coding>
<system value="http://hl7.org/fhir/cited-medium"/>
<code value="internet-without-issue"/>
<display value="Internet without issue"/>
</coding>
</citedMedium>
<articleDate value="2008-11-24"/>
</publicationForm>
<webLocation>
<classifier>
<coding>
<system value="http://hl7.org/fhir/artifact-url-classifier"/>
<code value="abstract"/>
<display value="Abstract"/>
</coding>
</classifier>
<url value="https://pubmed.ncbi.nlm.nih.gov/19029421/"/>
</webLocation>
<webLocation>
<classifier>
<coding>
<system value="http://hl7.org/fhir/artifact-url-classifier"/>
<code value="doi-based"/>
<display value="DOI Based"/>
</coding>
</classifier>
<url value="https://doi.org/10.1200/JCO.2007.15.9830"/>
</webLocation>
<classification>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="publishing-model"/>
<display value="Publishing Model"/>
<userSelected value="false"/>
</coding>
</type>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="Print-Electronic"/>
<display value="Print Electronic"/>
<userSelected value="false"/>
</coding>
</classifier>
</classification>
<classification>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="chemical"/>
<display value="Chemical"/>
<userSelected value="false"/>
</coding>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D000726"/>
<display value="Androgen Antagonists"/>
<userSelected value="false"/>
</coding>
</classifier>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D000903"/>
<display value="Antibiotics, Antineoplastic"/>
<userSelected value="false"/>
</coding>
</classifier>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D018906"/>
<display value="Antineoplastic Agents, Alkylating"/>
<userSelected value="false"/>
</coding>
</classifier>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D000972"/>
<display value="Antineoplastic Agents, Phytogenic"/>
<userSelected value="false"/>
</coding>
</classifier>
<classifier>
<coding>
<system
value="https://www.cas.org/support/documentation/chemical-substances"/>
<code value="35LT29625A"/>
<userSelected value="false"/>
</coding>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D004961"/>
<display value="Estramustine"/>
<userSelected value="false"/>
</coding>
</classifier>
<classifier>
<coding>
<system
value="https://www.cas.org/support/documentation/chemical-substances"/>
<code value="5V9KLZ54CY"/>
<userSelected value="false"/>
</coding>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D014747"/>
<display value="Vinblastine"/>
<userSelected value="false"/>
</coding>
</classifier>
<classifier>
<coding>
<system
value="https://www.cas.org/support/documentation/chemical-substances"/>
<code value="80168379AG"/>
<userSelected value="false"/>
</coding>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D004317"/>
<display value="Doxorubicin"/>
<userSelected value="false"/>
</coding>
</classifier>
<classifier>
<coding>
<system
value="https://www.cas.org/support/documentation/chemical-substances"/>
<code value="R9400W927I"/>
<userSelected value="false"/>
</coding>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D007654"/>
<display value="Ketoconazole"/>
<userSelected value="false"/>
</coding>
</classifier>
</classification>
<classification>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
</type>
<artifactAssessment>
<reference value="#meshHeading0"/>
<type value="ArtifactAssessment"/>
</artifactAssessment>
</classification>
<classification>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="publication-type"/>
<display value="Publication type"/>
</coding>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D017428"/>
<display value="Clinical Trial, Phase III"/>
<userSelected value="false"/>
</coding>
</classifier>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D016428"/>
<display value="Journal Article"/>
<userSelected value="false"/>
</coding>
</classifier>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D016449"/>
<display value="Randomized Controlled Trial"/>
<userSelected value="false"/>
</coding>
</classifier>
</classification>
<classification>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="knowledge-artifact-type"/>
<display value="Knowledge Artifact Type"/>
<userSelected value="false"/>
</coding>
</type>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
<userSelected value="false"/>
</coding>
</classifier>
<artifactAssessment>
<display value="Classifier added by Computable Publishing LLC"/>
</artifactAssessment>
</classification>
<classification>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="citation-subset"/>
<display value="Citation subset"/>
<userSelected value="false"/>
</coding>
</type>
<classifier>
<coding>
<system
value="https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset"/>
<code value="IM"/>
<display value="IM"/>
<userSelected value="false"/>
</coding>
</classifier>
</classification>
<contributorship>
<complete value="true"/>
<entry>
<contributor>
<reference value="#contributor0"/>
<type value="Practitioner"/>
<display value="Millikan RE"/>
</contributor>
<forenameInitials value="RE"/>
<affiliation>
<display
value="Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, 1155 Pressler, CPB7.3462, Houston, TX 77030, USA. rmillika@mdanderson.org"/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor1"/>
<type value="Practitioner"/>
<display value="Wen S"/>
</contributor>
<forenameInitials value="S"/>
</entry>
<entry>
<contributor>
<reference value="#contributor2"/>
<type value="Practitioner"/>
<display value="Pagliaro LC"/>
</contributor>
<forenameInitials value="LC"/>
</entry>
<entry>
<contributor>
<reference value="#contributor3"/>
<type value="Practitioner"/>
<display value="Brown MA"/>
</contributor>
<forenameInitials value="MA"/>
</entry>
<entry>
<contributor>
<reference value="#contributor4"/>
<type value="Practitioner"/>
<display value="Moomey B"/>
</contributor>
<forenameInitials value="B"/>
</entry>
<entry>
<contributor>
<reference value="#contributor5"/>
<type value="Practitioner"/>
<display value="Do KA"/>
</contributor>
<forenameInitials value="KA"/>
</entry>
<entry>
<contributor>
<reference value="#contributor6"/>
<type value="Practitioner"/>
<display value="Logothetis CJ"/>
</contributor>
<forenameInitials value="CJ"/>
</entry>
</contributorship>
</citedArtifact>
</Citation>
IG © 2024+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#2.0.0-ballot based on FHIR 6.0.0-ballot2. Generated 2024-11-21
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change